BIVICTRIX THER.PLC LS-,01

Share · GB00BNXH3K91 · A3CWZM (XLON)

Overview

No Price

n/a

Share Float & Liquidity

Free Float 57,67 %

Shares Float 47,59 M

Shares Outstanding 82,53 M

Company Profile for BIVICTRIX THER.PLC LS-,01 Share

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

AI Analysis of BIVICTRIX THER.PLC LS-,01

Click any analysis below to get instant AI insights from finAgent

Company Data

Name BIVICTRIX THER.PLC LS-,01

Company BiVictriX Therapeutics Plc

Website https://www.bivictrix.com

Primary Exchange

Frankfurt

WKN A3CWZM

ISIN GB00BNXH3K91

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Tiffany Jane Thorn

Country United Kingdom

Currency EUR

Employees 0,0 T

Address Bio Hub, SK10 4TG Macclesfield

IPO Date 2021-08-11

Ticker Symbols

Name	Symbol
Frankfurt	4DE.F
London	BVX.L

More Shares

Investors who hold BIVICTRIX THER.PLC LS-,01 also have the following shares in their portfolio:

Norddeutsche Landesbank -GZ- Express Z.03.04.30 VNA Unbekannt

Shaanxi Construction Machinery Co.,Ltd Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog